DNA

#2821
Ginkgo Bioworks Holdings, Inc. Class A Common Stock
9.5 6 USD
+2.47%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
9.50
9.75
년간 변동
5.37
10.64
일일 변동
+2.47%
월간 변동
+27.21%
6달 변화
+7.66%
년간 변동율
+7.66%
이전 종가
9.3 3
Open
9.5 9
저가
9.5 0
High
9.7 5
양
204
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 595.82 M
  • Employee 485
  • Founded 2008
  • CEO Jason Kelly
  • Website www.ginkgobioworks.com
  • Headquarter Delaware, United States
  • FIGI BBG00YPS1KY3
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-1.47
주가매출액비율
2.71

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

뉴스